PROTARA THERAPEUTICS INC (TARA)
Health Care · Biotechnology · NASDAQ
Clinical-stage biopharmaceutical company developing TARA-002 for bladder cancer and rare lymphatic malformations, and IV Choline Chloride for patients on parenteral support.
What PROTARA THERAPEUTICS INC does
Protara Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its primary asset, TARA-002, is an investigational cell therapy derived from Streptococcus pyogenes being studied for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations. The company is also developing IV Choline Chloride as a phospholipid substrate replacement therapy for patients requiring long-term parenteral support.
Recent developments
The company expects to complete enrollment for the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 and plans to submit a BLA for TARA-002 in lymphatic malformations in 2H 2027. Additionally, the ADVANCED-3 trial is being redesigned as an exploratory study to expand data collection across broader NMIBC patient populations.
From PROTARA THERAPEUTICS INC's filing of 2026-08-11.
Themes: oncology / cancer therapy, rare diseases, cell therapy, urothelial cancer, parenteral nutrition support
Fundamentals
- Price$2.50 as of 2026-10-21 close
- Market cap$148M as of 2026-08-07 (share count; price 2026-10-21)
- 1-year return-53.7% 2025-10-21 close $5.40 → 2026-10-21 close $2.50
- P/En/a negative earnings
- ROE-29.2% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no income tax expense.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.11 as of 2026-09-02
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How TARA compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$23M | -$22M | -$0.36 | -$15M† | — |
| Q1 FY2026 2026-03-31 | -$20M | -$18M | -$0.31 | -$21M | — |
| Q4 FY2025 2025-12-31 | -$19M† | -$17M† | -$0.38† | -$17M† | $24000† |
| Q3 FY2025 2025-09-30 | -$15M | -$13M | -$0.31 | -$12M† | $4000† |
| Q2 FY2025 2025-06-30 | -$17M | -$15M | -$0.35 | -$12M† | $22000† |
| Q1 FY2025 2025-03-31 | -$14M | -$12M | -$0.29 | -$15M | $44000 |
| Q4 FY2024 2024-12-31 | -$14M† | -$13M† | -$0.43† | -$9M† | $0† |
| Q3 FY2024 2024-09-30 | -$12M | -$11M | -$0.50 | -$8M† | $8000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$17M
- Short-term investments$125M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How PROTARA THERAPEUTICS INC looks technically
PROTARA THERAPEUTICS INC (TARA) is trading 45.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 99 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 46, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 67.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 45.5% below its 200-day average, the long-term trend line — a long-term downtrend | -45.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.43 | $3.43 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.70 | $4.70 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 36 calendar days ago — the swings before that are what the structure reading is measured on | 36 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 4.015. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 99 trading days ago — a "death cross", a bearish long-term signal | 99 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 46, with sellers in control | 45.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 35.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($2.29 to $3.10) — its "stochastic" reading is 33 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 32.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 26 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.82 | $7.82 |
|---|---|---|
| From the 52-week high | it is 67.3% below its 52-week high (its highest price of the past year) | -67.3% |
| Above the 52-week low | it is 11.5% above its 52-week low (its lowest price of the past year) | +11.6% |
| Below the 52-week high | it is 67.3% below its highest point of the past year | 67.3% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $800.00 (set on 2015-07-17) | $800.00 |
| Given back of the 52-week move | over the past year its closes ranged ($2.32 to $7.56), and it has recovered only a small part of its fall from last year’s high — 5% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.56 to $5.73. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 4.6% |
| From the all-time high | it is 99.7% below its all-time high | -99.7% |
| Nearest price level | it is trading 7.6% below a resistance level at $2.75 — a price it turned at twice since 2024-11-05, most recently on 2025-07-02. Since 2024-10-21 it has 0 such levels below the current price and 18 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +7.6% |
| All-time low | its lowest closing price on record is $1.04 (set on 2023-11-22) | $1.04 |
| Above the all-time low | it is 146.2% above its all-time low | +146.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 92% of the past ~6 months) | 92nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1904 between its high and its low — about 7.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1904 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.08 and $3.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.08 – $2.79 – $3.50 |
| Typical daily range (% of price) | its price moves about 7.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.4% |
| Stretch from the 200-day average | it is trading 11.2 daily ranges below its 200-day average price (45.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 11.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.03× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 3.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +3.5% |
|---|---|---|
| Open gap | it gapped 3.5% above the previous close today and has not traded back through the level it left behind at 2.33 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.5% |
| Gap filled | a 2.5% gap up opened on 2026-09-29 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +10.34% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 28.9 percentage points (the stock lost 27.9% while the market gained 1.0%) | -28.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 40.7 percentage points (the stock lost 37.1% while the market gained 3.6%) | -40.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 60.2 percentage points (the stock lost 51.7% while the market gained 8.5%) | -60.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 68.5 percentage points (the stock lost 54.0% while the market gained 14.6%) | -68.5% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 35% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.5% of the share price. | -34.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 45% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.66 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -45.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.18 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -19.5% |
Price levels it has turned at before
TARA last closed at $2.56 on 2026-10-20. Since 2024-10-21 it has turned at 0 prices below its last close and 18 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.75 | Resistance | 7.6% above the last close | turned there twice · 2024-11-05 to 2025-07-02 |
| $3.00 | Resistance | 17.4% above the last close | turned there five times · 2025-05-15 to 2025-09-17 |
| $3.21 | Resistance | 25.4% above the last close | turned there twice · 2025-03-04 to 2025-07-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $4.01.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $3.37 and $3.62 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $4.01.
This reading has stood for 22 trading days, since 2026-09-21.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Gapped up at the open (3%+) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$25.71 range $20.00 – $30.00; median $26.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TARA
- Consensus EPS estimate-$0.363 next reporting period, as of 2026-10-20
- Estimate change, 30 days$0.00 from -$0.363, on 2026-09-15, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is a clinical-stage entity with no generated revenue and a history of significant operating losses, which may continue for several years.","Future success is entirely dependent on the clinical development, regulatory approval, and potential commercialization of investigational products TARA-002 and IV Choline Chloride."]
What changed in the latest 10-Q
AI-assisted comparison of TARA's 10-Q filed 2026-05-13 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Accumulated deficit figure of approximately $320.2 million as of March 31, 2026 (newer filing)
- Cash and cash equivalents of approximately $177.4 million as of March 31, 2026 (newer filing)
- Specific naming of Phase 1a trial as 'ADVANCED-1' with October 2024 completion date (newer filing)
- Specific naming of Phase 1b trial as 'ADVANCED-1EXP' with September 2024 completion date (newer filing)
- February 2026 presentation of updated interim data from ADVANCED-2 trial (newer filing)
- Detailed efficacy data including 43 BCG-Unresponsive and 31 BCG-Naïve patients with January 28, 2026 data cutoff (newer filing)
- BCG-Unresponsive cohort CR rates: 65.7% at any time, 68.2% at 6 months, 33.3% at 12 months (newer filing)
- BCG-Naïve cohort CR rates: 72.4% at any time, 66.7% at 6 months, 57.9% at 12 months (newer filing)
- Kaplan-Meier maintenance data for both cohorts with specific percentages and confidence intervals (newer filing)
- Re-induction therapy conversion rates: 61.5% for BCG-Unresponsive, 66.7% for BCG-Naïve (newer filing)
- March 2026 announcement of 25th BCG-Unresponsive patient confirmation with 68.0% average six-month CR rate (newer filing)
- Reference to 41.9% as a comparison benchmark (newer filing)
- Expected completion of BCG-Unresponsive enrollment in second half of 2026 (newer filing)
- FDA agreement that BCG is not required as comparator and intravesical chemotherapy is acceptable (newer filing)
- Plan to initiate ADVANCED-3 trial in second half of 2026 (newer filing)
- Removed:
- Forward-looking statements cautionary language from opening (older filing had this, newer filing removed it from this section)
- Company overview paragraph describing NYC-based clinical-stage biopharmaceutical company (removed from newer filing)
- Reference to TARA-002 derived from OK-432 and Picibanil background (removed from newer filing)
- Mention of TARA-002 development in lymphatic malformations (LMs) (removed from newer filing)
- Reference to worldwide rights excluding Japan and Taiwan (removed from newer filing)
- Statement that 'Neither TARA-002 nor IV Choline Chloride have been approved for use' (removed from newer filing)
- April 2025 American Urology Association conference presentation data (removed, replaced with February 2026 data)
- April 16, 2025 data cutoff results with 5 BCG-Unresponsive patients (removed)
- April 2025 BCG-Unresponsive 100% CR rate at any time and 6 months (superseded by larger dataset)
- April 2025 BCG-Naïve 21-patient dataset with 76% CR rate at any time (superseded by larger dataset)
- Expectation to present interim analysis from approximately 25 six-month evaluable patients in Q1 2026 (removed as this was completed)
- Expectation to provide FDA discussion update in Q4 2025 (removed as this timing has passed)
- Description of adverse events as 'flu-like symptoms' (removed from newer filing)
- Reworded:
- Older: 'Phase 1a and 1b clinical trials' changed to newer: 'Phase 1a ADVANCED-1 and Phase 1b ADVANCED-1EXP trials'
- Older: 'is expected to be registrational' changed to newer: 'is designed to be registrational'
- Older: 'Every year in the U.S. there are approxima' (text cut off) to newer: 'Every year in the U.S. there are approximately' (text cut off at same point but confirms continuation)
- Older: 'We presented interim data from the ADVANCED-2 trial at the American Urology Association annual conference in April 2025' changed to newer: 'In February 2026, we presented updated interim data from our ongoing Phase 2 open-label ADVANCED-2 trial'
- Older: 'Cohort A of the Phase 2 has completed enrollment' changed to newer: 'Cohort A of the Phase 2 trial has completed enrollment'
- Older: 'T1 as defined as carcinoma' changed to newer: 'T1 defined as carcinoma'
- Older: 'The majority of adverse events were Grade 1 and transient with no Grade 3 or greater treatment-related adverse events' changed to newer: 'The majority of treatment-related adverse events, or TRAEs, were Grade 1 and transient with no Grade 3 or greater TRAEs'
- Older: 'The most common adverse events were in line with typical responses to bacterial immunopotentiation, such as flu-like symptoms. The most common urinary symptoms...' changed to newer: 'The most commonly occurring TRAEs were dysuria (14%), bladder spasm (9%), fatigue (7%) and micturition urgency (5%)'
- Older: 'Most bladder irritations resolved shortly after administration or within a few hours to a few days' removed and replaced with specific TRAE percentages
- Older: 'for patients receiving PS, which includes both nutrition and fluids' changed to newer: 'for patients receiving PS which includes both nutrition and fluids' (minor punctuation)
- Notes:
- Both texts are truncated at the IV Choline Chloride section ending with 'Every year in the U.S. there are approxima', preventing full comparison of that section.
- The newer filing reorganizes content and removes some introductory/overview material that appears in the older filing, making it a more focused clinical update document.
- Data progression shows significantly expanded patient numbers and follow-up timepoints in the newer filing compared to the April 2025 conference data from the older filing.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
- Last 180 days · read to 2026-10-170 buys · 1 sell ($882160) — 1 selling insider
Most recent open-market transaction: 2026-06-29. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TARA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding TARA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,516,224
- Reported value $28,711,976
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about TARA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
TARA had 5,791,421 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
TARA had 9.80% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.91 days to cover at the same settlement.
- Reported short interest (shares) 5,791,421
- Short interest (% of shares outstanding) 9.80%
- Prior settlement (shares) 4,417,095
- Reported change 31.11%
- Days to cover (reported) 2.91
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Ferring Pharmaceuticals
- Merck (MRK)
- AstraZeneca (AZN)
- Bristol Myers Squibb (BMY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TARA vs…
PROTARA THERAPEUTICS INC is found in…
Frequently asked questions
What does PROTARA THERAPEUTICS INC (TARA) do?
Protara Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its primary asset, TARA-002, is an investigational cell therapy derived from Streptococcus pyogenes being studied for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations. The company is also developing IV Choline Chloride as a phospholipid substrate replacement therapy for patients requiring long-term parenteral support.
What sector is PROTARA THERAPEUTICS INC (TARA) in?
PROTARA THERAPEUTICS INC (TARA) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are PROTARA THERAPEUTICS INC's (TARA) competitors?
Notable peers of PROTARA THERAPEUTICS INC (TARA) include Ferring Pharmaceuticals, Merck, AstraZeneca and Bristol Myers Squibb. This peer set is informational only — not financial advice.
Is PROTARA THERAPEUTICS INC (TARA) overbought or oversold right now?
PROTARA THERAPEUTICS INC (TARA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TARA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.